ArticleNature genetics2015
The genomic landscape of juvenile myelomonocytic leukemia.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 162 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 1 pooled it
16.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 1 synthesis or guideline pooled it, 306 citations in OpenAlex.
- Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.Cancer discovery · 2024Trial
- Trial
- Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.Pediatric blood & cancer · 2018Trial
- Trial
- Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing.Medical sciences (Basel, Switzerland) · 2026Article
- Genomic Characterization of Epigenetic Regulator Gene Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing.Epigenomes · 2026Article
- Review
- Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Molecular cancer therapeutics · 2026Article
- Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.Leukemia · 2026Article
- Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.Blood advances · 2026Article
- Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.Leukemia · 2026Article
- Bilateral testicular infiltration as the initial presentation of NRAS-mutant juvenile myelomonocytic leukemia: rapid molecular remission following azacitidine and haploidentical stem cell transplantation.Leukemia research reports · 2026Article
- Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.British journal of haematology · 2025Article
- Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.British journal of haematology · 2025Article
- Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity.British journal of haematology · 2025Article
- Innate immune mechanisms hijacked by leukemia-initiating stem cells for selective advantage and immune evasion in Ptpn11-associated JMML.Cell reports · 2025Article
- Primary disorders of polyubiquitination: Dual roles in autoinflammation and immunodeficiency.The Journal of experimental medicine · 2025Review
- Loss of Golga7 Suppresses Oncogenic Nras-Driven Leukemogenesis without Detectable Toxicity in Adult Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions.Blood neoplasia · 2025Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
47 authors at 20 institutions in 2 countries.
Elliot Stieglitz *Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Amaro N Taylor-Weiner *Broad Institute of MIT and Harvard, Cambridge, MA.
Tiffany Y ChangDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Laura C GelstonDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Yong-Dong WangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Tali MazorDepartment of Neurological Surgery, University of California, San Francisco, CA.
Emilio EsquivelDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Ariel YuDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Sara SeepoBroad Institute of MIT and Harvard, Cambridge, MA.
Scott OlsenHartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, TN.
Mara RosenbergBroad Institute of MIT and Harvard, Cambridge, MA.
Sophie L ArchambeaultDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Ghada AbusinStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA.
Kyle BeckmanDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
Patrick A BrownDepartment of Pediatrics, The Johns Hopkins Hospital, Baltimore, MA.
Michael BrionesDepartment of Pediatrics, Emory University School of Medicine, Aflac Cancer and Blood Disorder Center, Atlanta, GA.
Benjamin CarcamoDepartment of Pediatrics, Texas Tech University, El Paso, TX.
Todd CooperDepartment of Pediatrics, Seattle Children's Hospital, Seattle, WA.
Gary V DahlDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA.
Peter D EmanuelWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
Mark N FluchelDepartment of Pediatric Hematology Oncology, University of Utah, Salt Lake City, UT.
Rakesh K GoyalDepartment of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
Robert J HayashiDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO.
Johann HitzlerDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Christopher HuggePediatric Hematology Oncology, SSM Cardinal Glennon Children's Medical Center, Saint Louis, MO.
Y Lucy LiuWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
Yoav H MessingerDivision of Pediatric Hematology Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN.
Donald H MahoneyDepartment of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.
Philip MonteleonePediatric Hematology Oncology, Pediatric Specialists of Lehigh Valley Hospital, Bethlehem, PA.
Eneida R NemecekPediatric Bone Marrow Transplant Program, Oregon Health & Science University, Portland, OR.
Philip A RoehrsDepartment of Pediatrics, University of North Carolina at Chapel Hill, NC.
Reuven J SchoreDivision of Pediatric Oncology, Children's National Medical Center, Washington, DC.
Kimo C StineDepartment of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR.
Clifford M TakemotoDepartment of Pediatrics, The Johns Hopkins Hospital, Baltimore, MA.
Jeffrey A ToretskyDepartment of Pediatrics, Georgetown University, Washington, DC.
Joseph F CostelloDepartment of Neurological Surgery, University of California, San Francisco, CA.
Adam B OlshenHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
Chip StewartBroad Institute of MIT and Harvard, Cambridge, MA.
Yongjin LiDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Robert B GerbingDepartment of Statistics, Children's Oncology Group, Monrovia, CA.
Todd A AlonzoKeck School of Medicine, University of Southern California, Los Angeles, CA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA.
Tanja GruberDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Todd GolubBroad Institute of MIT and Harvard, Cambridge, MA.
Kimberly StegmaierBroad Institute of MIT and Harvard, Cambridge, MA.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA.
University of California, San Francisco · USBroad Institute · USSt. Jude Children's Research Hospital · USJohns Hopkins Hospital · USWinthrop Rockefeller Foundation · USBaylor College of Medicine · USCardinal Glennon Children’s Medical Center · USChildren's Hospital of Pittsburgh · USChildren’s Minnesota - St. Paul Hospital · USChildren's National · USChildren's Oncology Group · USEmory University · USGeorgetown University · USHospital for Sick Children · CALehigh University · USOregon Health & Science University · USSeattle Children's Hospital · USStanford Medicine · USTexas Tech University · USUniversity of Arkansas for Medical Sciences · US
Funding
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MTranslational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MMechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasiaR01CA173085 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRAUN, BENJAMIN · 2013 to 2017
$1.6MNCI NIH HHS 1U10CA180899NCI NIH HHS 5P30CA082103NCI NIH HHS 5U10CA098543NCI NIH HHS P30 CA021765NCI NIH HHS P30 CA082103NCI NIH HHS P30CA82103NCI NIH HHS R01 CA173085NCI NIH HHS R01CA173085NCI NIH HHS T32 CA128583NCI NIH HHS T32CA128583NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180899
Abstract
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. Mutations in NF1, NRAS, KRAS, PTPN11 or CBL occur in 85% of patients, yet there are currently no risk stratification algorithms capable of predicting which patients will be refractory to conventional treatment and could therefore be candidates for experimental therapies. In addition, few molecular pathways aside from the RAS-MAPK pathway have been identified that could serve as the basis for such novel therapeutic strategies. We therefore sought to genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia to expand knowledge of the mutational spectrum in JMML. We identified recurrent mutations in genes involved in signal transduction, splicing, Polycomb repressive complex 2 (PRC2) and transcription. Notably, the number of somatic alterations present at diagnosis appears to be the major determinant of outcome.
Indexed as
MutationAcute DiseaseChildChild, PreschoolDisease-Free SurvivalDisease ProgressionDNA Copy Number VariationsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHigh-Throughput Nucleotide SequencingHumansInfantLeukemia, MyeloidLeukemia, Myelomonocytic, JuvenileMale
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.